84 related articles for article (PubMed ID: 17026791)
1. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer.
Azuma M; Danenberg KD; Iqbal S; El-Khoueiry A; Zhang W; Yang D; Koizumi W; Saigenji K; Danenberg PV; Lenz HJ
Clin Colorectal Cancer; 2006 Sep; 6(3):214-8. PubMed ID: 17026791
[TBL] [Abstract][Full Text] [Related]
2. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
Yang B; Chen J; Zhang X; Cao J
Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
[TBL] [Abstract][Full Text] [Related]
3. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
[TBL] [Abstract][Full Text] [Related]
4. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
5. EGFRvIII mutation in lung cancer correlates with increased EGFR copy number.
Sasaki H; Kawano O; Endo K; Yukiue H; Yano M; Fujii Y
Oncol Rep; 2007 Feb; 17(2):319-23. PubMed ID: 17203167
[TBL] [Abstract][Full Text] [Related]
6. Lack of the type III epidermal growth factor receptor mutation in colorectal cancer.
Spindler KL; Olsen DA; Nielsen JN; Brandslund I; Poulsen HS; Villingshøj M; Jakobsen A
Anticancer Res; 2006; 26(6C):4889-93. PubMed ID: 17214357
[TBL] [Abstract][Full Text] [Related]
7. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
8. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Olsen DA; Corydon T; Lorentzen KA; Knudsen HJ; Jeppesen U; Brandslund I; Jakobsen A
Clin Cancer Res; 2008 Jun; 14(11):3278-82. PubMed ID: 18519753
[TBL] [Abstract][Full Text] [Related]
9. EGFR and EGFRvIII expression in primary breast cancer and cell lines.
Rae JM; Scheys JO; Clark KM; Chadwick RB; Kiefer MC; Lippman ME
Breast Cancer Res Treat; 2004 Sep; 87(1):87-95. PubMed ID: 15377854
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
[TBL] [Abstract][Full Text] [Related]
11. High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor.
Deng Y; Kurland BF; Wang J; Bi J; Li W; Rao S; Lan P; Lin T; Lin E
Am J Clin Oncol; 2009 Jun; 32(3):245-52. PubMed ID: 19451802
[TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells.
Theodoropoulou M; Arzberger T; Gruebler Y; Jaffrain-Rea ML; Schlegel J; Schaaf L; Petrangeli E; Losa M; Stalla GK; Pagotto U
J Endocrinol; 2004 Nov; 183(2):385-94. PubMed ID: 15531726
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS
Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
17. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.
Gan HK; Cvrljevic AN; Johns TG
FEBS J; 2013 Nov; 280(21):5350-70. PubMed ID: 23777544
[TBL] [Abstract][Full Text] [Related]
18. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer.
Lubbe WJ; Zhou ZY; Fu W; Zuzga D; Schulz S; Fridman R; Muschel RJ; Waldman SA; Pitari GM
Clin Cancer Res; 2006 Mar; 12(6):1876-82. PubMed ID: 16551873
[TBL] [Abstract][Full Text] [Related]
19. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer.
Cunningham MP; Essapen S; Thomas H; Green M; Lovell DP; Topham C; Marks C; Modjtahedi H
Int J Oncol; 2005 Aug; 27(2):317-25. PubMed ID: 16010411
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
